KRAS mutations can be observed early in neoplastic development (i.e., even in low-grade PanIN and IPMN) consequently increasing to more than 90% of PDAC carrying activating KRAS mutations as major driver event. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.